Unknown

Dataset Information

0

Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?


ABSTRACT: Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the mGlu2 positive allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on negative symptoms in patients.

SUBMITTER: Hopkins CR 

PROVIDER: S-EPMC3582287 | biostudies-other | 2013 Feb

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC3057427 | biostudies-literature
| S-EPMC4096224 | biostudies-literature
| S-EPMC4748441 | biostudies-literature
| S-EPMC3696790 | biostudies-literature
| S-EPMC6952546 | biostudies-literature
| S-EPMC3172159 | biostudies-other
| S-EPMC10405528 | biostudies-literature
| S-EPMC8391421 | biostudies-literature
| S-EPMC6725607 | biostudies-literature
| S-EPMC10860701 | biostudies-literature